• Raphael Pharmaceutical posted a net loss of $229,000 for the quarter ended March 31, 2026, narrowing 47% from a year earlier.
• Operating loss narrowed 48% to $223,000, while research and development expense fell 49% to $37,000.
• General and administrative costs dropped 47% to $186,000; financial expense, net, widened to $6,000.
• No revenue was reported; cash and cash equivalents totaled $1,000 as of March 31, 2026.
• Outlook called for about $1 million in R&D spending over the next 12 months, with existing cash expected to fund needs through the third quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raphael Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-056181), on May 14, 2026, and is solely responsible for the information contained therein.